AR and prostate carcinoma: In comparison with clinically approved AR antagonists (such as ENZ, etc.), ARD-61 exhibited stronger anti-proliferative and pro-apoptotic effects and attenuated the expression of AR target genes in prostate cancer cells in vivo and in vitro.